PDF(Pubmed)
Abstract：
Alzheimer\'s disease (AD) is a complex neurodegenerative process, also considered a metabolic condition due to alterations in glucose metabolism and insulin signaling pathways in the brain, which share similarities with diabetes. This study aimed to investigate the therapeutic effects of benfotiamine (BFT), a vitamin B1 analog, in the early stages of the neurodegenerative process in a sporadic model of Alzheimer\'s-like disease induced by intracerebroventricular injection of streptozotocin (STZ). Supplementation with 150 mg/kg of BFT for 7 days reversed the cognitive impairment in short- and long-term memories caused by STZ in rodents. We attribute these effects to BFT\'s ability to modulate glucose transporters type 1 and 3 (GLUT1 and GLUT3) in the hippocampus, inhibit GSK3 activity in the hippocampus, and modulate the insulin signaling in the hippocampus and entorhinal cortex, as well as reduce the activation of apoptotic pathways (BAX) in the hippocampus. Therefore, BFT emerges as a promising and accessible intervention in the initial treatment of conditions similar to AD.
摘要：
阿尔茨海默病(AD)是一个复杂的神经退行性过程,也被认为是由于大脑中葡萄糖代谢和胰岛素信号通路的改变而导致的代谢状况，与糖尿病有相似之处。本研究旨在探讨苯硫胺（BFT）的治疗效果，维生素B1类似物，在脑室内注射链脲佐菌素（STZ）引起的偶发性阿尔茨海默病样疾病模型中神经退行性过程的早期阶段。补充150mg/kg的BFT7天可以逆转由STZ引起的啮齿动物短期和长期记忆的认知障碍。我们将这些效应归因于BFT调节海马中1型和3型葡萄糖转运蛋白（GLUT1和GLUT3）的能力，抑制海马中的GSK3活性，调节海马和内嗅皮层的胰岛素信号，以及减少海马中凋亡途径（BAX）的激活。因此,BFT在类似于AD的病症的初始治疗中作为有希望的和可获得的干预出现。
